Wednesday 3 July 2024

The Pharma Letter Podcast — Episode 3 — Psychedelics in medicine

Pharmaceutical
Guy Martin
18 August 2021
podcast-episode3

More on this story...

Pharmaceutical
Psychedelics specialist starts Phase IIa test of lead candidate
7 April 2021
Biotechnology
GSK punts $2.2 billion on global collaboration in immuno-neurology
3 July 2021
Pharmaceutical
BRIEF—Small Pharma scores Innovation Passport designation for SPL026
21 October 2021
Psychedelics
Reunion Neuroscience closes $103 million Series A financing
3 May 2024


More ones to watch >


Today's issue

Pharmaceutical
Access to medicines key to British voters, survey shows
3 July 2024
Generics
US authorities clear Mylan in long-running antitrust probe
3 July 2024
Biotechnology
Touchlight and LeninBio announce link up
3 July 2024
Pharmaceutical
Pentixapharm pads pipeline with strategic acquisition
3 July 2024
Biotechnology
Beacon Therapeutics raises $170 million in a Series B financing
3 July 2024
Biotechnology
Lilly's Alzheimer’s drug Kisunla wins FDA approval
3 July 2024
Biotechnology
First COPD nod could add billions to Dupixent revenue
3 July 2024

Company Spotlight

A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.




More Features in Pharmaceutical

Access to medicines key to British voters, survey shows
3 July 2024
Pentixapharm pads pipeline with strategic acquisition
3 July 2024
Striking results in Phase III Parkinson’s trial
3 July 2024
ThirtyFiveBio receives grant to continue work on GPR35 blockers
2 July 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze